Press Release: Silo Pharma Secures Patent that May be Used for Psychedelics Delivery Technology

CANNANNEW REPORT

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Silo Pharma Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Patent Office issued a notice of allowance for its technology/method patent covering an isolated homing peptide and how it can help deliver drugs to the central nervous system (CNS). “We are pleased to have been granted this patent by the United States Patent and Trademark Office for our novel homing peptide,” said CEO Eric Weisblum in a press release announcing the USPTO’s decision. “We will continue to expand our intellectual property portfolio related to markets where our novel therapeutics can be applied.” After filing a provisional patent application, an examiner from the USPTO determines if an invention qualifies for a patent. Once the examiner decides to grant the patent, they issue a notice of allowance, which means that the patent is valid after paying registration fees. The company’s efforts to secure patents are the cornerstone of its strategy to develop and license therapeutics. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Bringing Products to Market Silo Pharma initially entered into an exclusive agreement with the University of Maryland-Baltimore to license its patented homing peptides targeting rheumatoid arthritis (RA)—a market that’s projected to reach nearly $63 billion by 2027. Management believes that the same technologies could also address a much larger market for central nervous system therapeutics. According to Global Industry Analysts, the global CNS therapeutics market could reach more than $132 billion by 2024. The homing peptides work by helping conventional therapeutics better target diseased tissue. Through better targeting, the company could enhance efficacy and minimize toxicity by potentially reducing the amount of active ingredients…

Excerpt only …
READ MORE BELOW
Source : Press Release: Silo Pharma Secures Patent that May be Used for Psychedelics Delivery Technology

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.